These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25795139)

  • 1. Response to: Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
    Spitali P; Aartsma-Rus A; 't Hoen PA
    Neuromuscul Disord; 2015 May; 25(5):446-7. PubMed ID: 25795139
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
    Zocevic A; Rouillon J; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2015 May; 25(5):444-6. PubMed ID: 25791581
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
    Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
    Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.
    Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
    Am J Pathol; 2016 May; 186(5):1302-12. PubMed ID: 26963343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy.
    Strandberg K; Ayoglu B; Roos A; Reza M; Niks E; Signorelli M; Fasterius E; Pontén F; Lochmüller H; Domingos J; Ala P; Muntoni F; Aartsma-Rus A; Spitali P; Nilsson P; Szigyarto CA
    J Neuromuscul Dis; 2020; 7(3):231-246. PubMed ID: 32390640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse.
    Nico B; Corsi P; Ria R; Crivellato E; Vacca A; Roccaro AM; Mangieri D; Ribatti D; Roncali L
    Neuroscience; 2006 Jul; 140(3):835-48. PubMed ID: 16650610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breathe Duchenne: what natural history studies tell us about the progression of pulmonary morbidity in Duchenne muscular dystrophy.
    Mayer OH; Aliverti A; Meier T
    Neuromuscul Disord; 2018 Nov; 28(11):910-913. PubMed ID: 30266222
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
    Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
    Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
    Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
    J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
    Heutinck L; Kampen NV; Jansen M; Groot IJ
    J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early symptoms of Duchenne muscular dystrophy--description of cases of an 18-month-old and an 8-year-old patient.
    Iwańczak F; Stawarski A; Potyrała M; Siedlecka-Dawidko J; Agrawal GS
    Med Sci Monit; 2000; 6(3):592-5. PubMed ID: 11208376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. True euglycemic diabetic ketoacidosis in a person with type 2 diabetes and Duchenne muscular dystrophy.
    Lee SH; Park JH; Hong MK; Hyeon S; Kim MY; Lee SE; Ahn J; Kim J
    Diabetes Res Clin Pract; 2011 Apr; 92(1):e7-8. PubMed ID: 21216484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive respiratory insufficiency in the absence of cardiac disease in late-stage Duchenne muscular dystrophy.
    Finsterer J; Stöllberger C; Meng G
    Respir Care; 2013 Mar; 58(3):e28-30. PubMed ID: 22781000
    [No Abstract]   [Full Text] [Related]  

  • 14. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.
    Savino W; Pinto-Mariz F; Mouly V
    Methods Mol Biol; 2018; 1687():219-227. PubMed ID: 29067667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study.
    Wren TA; Bluml S; Tseng-Ong L; Gilsanz V
    AJR Am J Roentgenol; 2008 Jan; 190(1):W8-12. PubMed ID: 18094282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist.
    Ames WA; Hayes JA; Crawford MW
    Paediatr Anaesth; 2005 Jan; 15(1):3-8. PubMed ID: 15649156
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.
    Zhang H; Zhu Y; Sun Y; Liang Y; Li Y; Zhang Y; Deng L; Wen X; Zhang C
    Dis Markers; 2015; 2015():141856. PubMed ID: 25852218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.